Shots:

• The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in patients with HER2-positive eBC- being treated with neoadjuvant and adjuvant setting
• The P-III FeDeriCa study results: reduction in the time spent for receiving treatment- loading dose & maintenance dose (8min. & 5min. vs 150min. & 60min.-150min.); safety profile is consistent with IV regimen respectively
• The FDC regimen combines Perjeta and Herceptin via Halozyme Therapeutics’ Enhanze drug delivery technology- which is based on rHuPH20 enzyme- work by optimizing SC drug delivery to co-administer therapies

Click here to­ read full press release/ article

Ref: Roche | Image: Roche